<DOC>
	<DOCNO>NCT00544466</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy drug , fludarabine phosphate melphalan , HT donor stem cell transplant help stop growth cancer cell . It also help stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving HT together fludarabine phosphate melphalan transplant may stop happen . PURPOSE : This clinical trial study helical tomotherapy ( HT ) , fludarabine phosphate , melphalan follow donor stem cell transplant treat patient hematologic malignancy .</brief_summary>
	<brief_title>Helical Tomotherapy , Fludarabine Phosphate , Melphalan Followed By Donor Stem Cell Transplant Treating Patients With Hematologic Malignancies</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To assess feasibility term toxicity safety HT combination Fludarabine ( fludarabine phosphate ) Melphalan preparative regimen allogeneic stem cell transplantation patient Hematological Malignancies : acute lymphoblastic leukemia ( ALL ) , acute myeloid leukemia ( AML ) , myelodysplastic syndrome ( MDS ) . SECONDARY OBJECTIVES : I . To evaluate within confines pilot study , incidence neutrophil platelet engraftment , survival day +180 , overall survival , disease free survival patient Hematological Malignancies : ALL , AML , MDS . II . To evaluate incidence primary secondary engraftment failure , incidence relapse , incidence acute chronic transplant related complication , include veno-occlusive disease liver ( VOD ) , organ toxicity , secondary malignancy , include treatment-related myelodysplastic syndrome , acute chronic graft-versus-host disease ( GVHD ) , well post-transplant chimerism . OUTLINE : PREPARATIVE REGIMEN* : Patients receive fludarabine phosphate intravenously ( IV ) day -7 -3 melphalan IV day -2 . Patients also undergo HT twice daily day -7 -4 . TRANSPLANTATION : Patients undergo allogeneic hematopoietic stem cell transplantation day 0 . NOTE : *Treatment begin 2 day earlier patient receive tacrolimus and/or sirolimus GVHD prophylaxis . After completion study treatment , patient follow periodically 2 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Recipient , recipient 's parent , recipient 's legal guardian must sign voluntary , informed consent accordance institutional federal guideline Must histopathologically confirm diagnosis one follow category : AML MDS intermediate highrisk disease ALL Children adult age significant morbidity , determine primary bone marrow transplant ( BMT ) doctor ( MD ) , approve principal investigator ( PI ) Able lie supine full body cast approximately 30 minute , anticipated duration treatment session ; young patient deep conscious sedation may require Performance status evaluate Zubrod Karnofsky ( KPS ) Performance Scales patient &gt; 16 year Lanksy Performance Scale child = &lt; 16 year must score &gt; = 70 % Adequate cardiac function : cardiac ejection fraction &gt; 50 % multi gated acquisition scan ( MUGA ) scan and/or echocardiogram Adequate pulmonary function : adult ( old 16 year ) : diffuse capacity carbon monoxide ( DLCO ) &gt; 50 % ; young child pulmonary function test ( PFT ) applicable : assessment pediatrician pulmonary consult Adequate renal function demonstrate : creatinine clearance glomerular filtration rate ( GFR ) &gt; 60 cc/min ( 24 hour urine collection ) Serum glutamic oxaloacetic transaminase ( SGOT ) serum glutamic pyruvic transaminase ( SGPT ) = &lt; 5.0 time institutional upper limit normal Patients must less 15 % peripheral blast Pretreatment test must preform within 30 day prior initiation highdose chemotherapy No medical and/or psychosocial problem , opinion primary physician principle investigator would place patient unacceptable risk regimen Patients Acute Undifferentiated Leukemia ( AUL ) , i.e . lymphoid myeloid marker Previous radiation therapy 20 % bone marrow contain area , area exceed 2000 cGy Patients Fanconi Anemia Major medical psychiatric disorder would seriously compromise patient tolerance regimen Human immunodeficiency virus ( HIV ) infection Evidence Hepatitis B C infection evidence cirrhosis Uncontrolled viral , bacterial fungal infection Patients recent ( within 4 week ) serious viral , fungal , bacterial infection exclude Patients radiographic change indicate pulmonary disease , include limited : pulmonary nodule , infiltrates , pleural effusion exclude unless clear pulmonary biopsy show evidence active pulmonary disease</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>acute myeloid leukemia multilineage dysplasia follow myelodysplastic syndrome</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia del ( 5q )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>untreated childhood acute myeloid leukemia myeloid malignancy</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>